Business Context and Reporting Period
Tenon Medical, Inc. (Tenon), a Delaware corporation and emerging growth company, filed this Form 8-K on September 5, 2024. The report details a private placement offering completed on the same date to raise capital through the issuance of Series B Preferred Stock and warrants.
Key Financial Metrics and Transaction Details
- Aggregate Offering Price: $550,000
- Securities Issued: 86,454 shares of Series B Preferred Stock and warrants to purchase 16,214 shares of Common Stock.
- Purchase Price: $6.3625 per share of Series B Preferred Stock.
- Warrant Terms: Exercise price of $4.2756 per share with a five-year term.
- Conversion Price: $5.09 per share for Series B Preferred Stock.
- Stated Value: Includes an annual accrual rate of 6%.
Material Changes and Terms
The filing represents a material change in the company's capital structure. Key terms include:
- Conversion Rights: Holders may convert Series B Preferred Stock into Common Stock at any time. The Company has the right to require conversion of 50% of the Preferred Stock if the 15-day VWAP of Common Stock exceeds 250% of the Conversion Price, or if the Company achieves $2.25 million in revenue in a single quarter.
- Liquidation Preference: Holders are entitled to the greater of the Stated Value plus accrued dividends or the value upon conversion. In a "Deemed Liquidation" (e.g., merger or sale), if the preference is less than 110% of the stated value, the dividend rate increases to 10%.
- Anti-Dilution: Weighted average anti-dilution protection applies to Dilutive Issuances, subject to stockholder approval.
- Voting Caps: Voting rights for individual holders are capped at 9.99% (or 4.99% if selected).
- Registration Rights: The Company must file a registration statement for the underlying Common Stock within 120 days of the Closing Date.
Guidance, Risks, and Contingencies
The filing does not provide updated financial guidance, revenue forecasts, or management commentary regarding future operational performance. The primary contingency noted is the requirement to file a registration statement within 120 days. The transaction was conducted under Section 4(a)(2) and Regulation 506(b) exemptions from registration.
Investor Verification Checklist
- Verify the effective date of the registration statement for the underlying Common Stock (required within 120 days of September 5, 2024).
- Review the full Certificate of Designations (Exhibit 10.2) for specific definitions of "Deemed Liquidation" and anti-dilution exceptions.
- Confirm the current trading volume and VWAP of Common Stock to assess the likelihood of the Company exercising its forced conversion rights.
- Monitor the Company's quarterly revenue reports to determine if the $2.25 million threshold for forced conversion is met.